Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases

A technology for hypertriglyceridemia and a composition is applied in the field of pharmaceutical compositions for preventing or treating hypertriglyceridemia or hypertriglyceridemia-related diseases, and can solve the problem of increasing atherosclerosis. risks, etc.

Inactive Publication Date: 2014-09-17
DAEWOONG PHARM CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the link between hypertriglyceridemia and cardiovascular diseases such as atherosclerosis is unclear, hypertriglyceridemia is known to increase the risk of atherosclerosis (Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor (triglyceride is an independent coronary heart disease risk factor evidence). Am J Cardiol2000; 86:943-9; Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis Role in atherosclerosis). Curr Atheroscler Rep2007; 9:110-5; Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL( Association of fasting and non-fasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoprotein and small dense LDL). Curr Opin Lipidol 2008; 19:355-61)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
  • Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
  • Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Evaluation of triglyceride inhibitory activity in hypercholesterolemia-induced animals

[0032] (1) Test method

[0033] Male New Zealand white rabbits were used as test animals. All animals except the G1 group animals (negative control group, n=4) were fed with a high-cholesterol meal sterilized by irradiation, i.e. DYET #620007 (Purina #5321 food, containing 1% cholesterol, Dyets, Inc., Bethlehem ( Bethlehem), PA18017), which was purchased from Central Lab. Animal Inc. To induce hypercholesterolemia, animals were provided with meals over 8 weeks. After blood samples are collected from animals, they are subjected to serum biochemical analysis. Animals with a total cholesterol level of approximately 870 mg / dL were selected as hypercholesterolemia induced animals. The test material was dissolved in saline containing 0.5% sodium carboxymethylcellulose and 1% Tween80, and then administered directly to the stomach using an oral syringe fitted with a latex cath...

Embodiment 2

[0042] Example 2 Evaluation of Triglyceride Inhibitory Activity in Animals Inducing Hypertriglyceridemia and Hypercholesterolemia

[0043] (1) Test method

[0044] Male New Zealand white rabbits were used as test animals. All animals except the G1 group animals (negative control group) were fed an irradiated hypertriglyceridemic and high cholesterol meal, DYET #621082 (Purina #5321 food with 0.5% cholesterol, 14% coconut oil and 2% maltodextrin, Dyets Company, Bethlehem, PA 18017), which were purchased from Saeronbio Company. To induce hypertriglyceridemia and hypercholesterolemia, animals were provided with meals over 4 weeks. After blood samples are collected from animals, they are subjected to serum biochemical analysis. Animals showing significant changes in total cholesterol levels and triglyceride levels compared to untreated controls were selected. Selected animals were divided into 4 groups according to total cholesterol levels and triglyceride levels, whereby all ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and a calcium channel blocker or a fibrate as active ingredients.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating hypertriglyceridemia or diseases related to hypertriglyceridemia. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-related diseases, which comprises (4S,5R)-5-[3, 5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl )phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or a pharmaceutically acceptable salt thereof and a calcium channel blocker or fibrate. Background technique [0002] Hyperlipidemia involves abnormally high levels of any or all lipids and / or lipoproteins in the blood. Depending on the type of lipids that are elevated, hyperlipidemia can be classified as hypercholesterolemia, hypertriglyceridemia, or mixed hyperlipidemia with both. Triglycerides are known to be one of the independent risk factors for atheros...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/421A61K31/42C07D263/06A61P9/12
CPCC07D263/22A61K31/421A61K31/4178A61K31/4184A61P1/18A61P3/06A61P7/00A61P9/10A61P9/12A61P43/00A61K2300/00A61K31/42C07D263/06A61K31/216A61K31/44A61K2121/00A61K31/41A61K31/4422A61K45/06
Inventor 李钟郁李相昊林泽周高银志
Owner DAEWOONG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com